vs
ACNB CORP（ACNB）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
ACNB CORP的季度营收约是REGENXBIO Inc.的1.6倍（$47.2M vs $30.3M），ACNB CORP净利率更高（22.9% vs -221.3%，领先244.2%），REGENXBIO Inc.同比增速更快（43.0% vs 42.2%），ACNB CORP自由现金流更多（$52.6M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 22.1%）
ACNB集团是总部位于美国宾夕法尼亚州的金融控股公司，提供零售及商业银行服务、财富管理、信托服务、财产及意外伤害保险等金融产品，主要服务宾夕法尼亚州中南部、马里兰州北部的当地居民及中小企业客户。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
ACNB vs RGNX — 直观对比
营收规模更大
ACNB
是对方的1.6倍
$30.3M
营收增速更快
RGNX
高出0.8%
42.2%
净利率更高
ACNB
高出244.2%
-221.3%
自由现金流更多
ACNB
多$105.4M
$-52.8M
两年增速更快
RGNX
近两年复合增速
22.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $47.2M | $30.3M |
| 净利润 | $10.8M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 27.9% | -190.0% |
| 净利率 | 22.9% | -221.3% |
| 营收同比 | 42.2% | 43.0% |
| 净利润同比 | 63.8% | -31.2% |
| 每股收益（稀释后） | $1.10 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACNBRGNX
| Q4 25 | $47.2M | $30.3M | ||
| Q3 25 | $50.9M | $29.7M | ||
| Q2 25 | $50.3M | $21.4M | ||
| Q1 25 | $43.5M | $89.0M | ||
| Q4 24 | $33.2M | $21.2M | ||
| Q3 24 | $34.1M | $24.2M | ||
| Q2 24 | $33.3M | $22.3M | ||
| Q1 24 | $31.6M | $15.6M |
净利润ACNBRGNX
| Q4 25 | $10.8M | $-67.1M | ||
| Q3 25 | $14.9M | $-61.9M | ||
| Q2 25 | $11.6M | $-70.9M | ||
| Q1 25 | $-272.0K | $6.1M | ||
| Q4 24 | $6.6M | $-51.2M | ||
| Q3 24 | $7.2M | $-59.6M | ||
| Q2 24 | $11.3M | $-53.0M | ||
| Q1 24 | $6.8M | $-63.3M |
毛利率ACNBRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率ACNBRGNX
| Q4 25 | 27.9% | -190.0% | ||
| Q3 25 | 37.2% | -176.3% | ||
| Q2 25 | 29.7% | -296.3% | ||
| Q1 25 | -1.3% | 13.6% | ||
| Q4 24 | 24.8% | -242.1% | ||
| Q3 24 | 27.6% | -256.6% | ||
| Q2 24 | 42.8% | -251.3% | ||
| Q1 24 | 26.9% | -408.8% |
净利率ACNBRGNX
| Q4 25 | 22.9% | -221.3% | ||
| Q3 25 | 29.2% | -208.3% | ||
| Q2 25 | 23.2% | -331.8% | ||
| Q1 25 | -0.6% | 6.8% | ||
| Q4 24 | 19.9% | -241.3% | ||
| Q3 24 | 21.1% | -246.3% | ||
| Q2 24 | 33.9% | -237.7% | ||
| Q1 24 | 21.4% | -405.4% |
每股收益（稀释后）ACNBRGNX
| Q4 25 | $1.10 | $-1.30 | ||
| Q3 25 | $1.42 | $-1.20 | ||
| Q2 25 | $1.11 | $-1.38 | ||
| Q1 25 | $-0.03 | $0.12 | ||
| Q4 24 | $0.77 | $-0.99 | ||
| Q3 24 | $0.84 | $-1.17 | ||
| Q2 24 | $1.32 | $-1.05 | ||
| Q1 24 | $0.80 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $65.6M | $230.1M |
| 总债务越低越好 | $255.4M | — |
| 股东权益账面价值 | $420.0M | $102.7M |
| 总资产 | $3.2B | $453.0M |
| 负债/权益比越低杠杆越低 | 0.61× | — |
8季度趋势，按日历期对齐
现金及短期投资ACNBRGNX
| Q4 25 | $65.6M | $230.1M | ||
| Q3 25 | $102.1M | $274.2M | ||
| Q2 25 | $103.1M | $323.3M | ||
| Q1 25 | $123.6M | $267.9M | ||
| Q4 24 | $47.3M | $234.7M | ||
| Q3 24 | $58.1M | $255.5M | ||
| Q2 24 | $86.3M | $290.4M | ||
| Q1 24 | $53.1M | $338.7M |
总债务ACNBRGNX
| Q4 25 | $255.4M | — | ||
| Q3 25 | $255.4M | — | ||
| Q2 25 | $255.4M | — | ||
| Q1 25 | $255.3M | — | ||
| Q4 24 | $255.3M | — | ||
| Q3 24 | $255.3M | — | ||
| Q2 24 | $255.3M | — | ||
| Q1 24 | $255.3M | — |
股东权益ACNBRGNX
| Q4 25 | $420.0M | $102.7M | ||
| Q3 25 | $408.6M | $161.5M | ||
| Q2 25 | $395.2M | $213.7M | ||
| Q1 25 | $386.9M | $274.2M | ||
| Q4 24 | $303.3M | $259.7M | ||
| Q3 24 | $306.8M | $301.4M | ||
| Q2 24 | $289.3M | $348.3M | ||
| Q1 24 | $279.9M | $390.7M |
总资产ACNBRGNX
| Q4 25 | $3.2B | $453.0M | ||
| Q3 25 | $3.3B | $525.2M | ||
| Q2 25 | $3.3B | $581.0M | ||
| Q1 25 | $3.3B | $490.9M | ||
| Q4 24 | $2.4B | $466.0M | ||
| Q3 24 | $2.4B | $519.1M | ||
| Q2 24 | $2.5B | $569.4M | ||
| Q1 24 | $2.4B | $629.2M |
负债/权益比ACNBRGNX
| Q4 25 | 0.61× | — | ||
| Q3 25 | 0.62× | — | ||
| Q2 25 | 0.65× | — | ||
| Q1 25 | 0.66× | — | ||
| Q4 24 | 0.84× | — | ||
| Q3 24 | 0.83× | — | ||
| Q2 24 | 0.88× | — | ||
| Q1 24 | 0.91× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $53.6M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $52.6M | $-52.8M |
| 自由现金流率自由现金流/营收 | 111.4% | -174.0% |
| 资本支出强度资本支出/营收 | 2.3% | 1.7% |
| 现金转化率经营现金流/净利润 | 4.96× | — |
| 过去12个月自由现金流最近4个季度 | $92.2M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流ACNBRGNX
| Q4 25 | $53.6M | $-52.3M | ||
| Q3 25 | $23.2M | $-56.0M | ||
| Q2 25 | $17.8M | $-49.3M | ||
| Q1 25 | $-71.0K | $33.6M | ||
| Q4 24 | $39.8M | $-31.6M | ||
| Q3 24 | $13.6M | $-40.5M | ||
| Q2 24 | $9.7M | $-45.5M | ||
| Q1 24 | $10.8M | $-55.5M |
自由现金流ACNBRGNX
| Q4 25 | $52.6M | $-52.8M | ||
| Q3 25 | $22.8M | $-56.5M | ||
| Q2 25 | $17.6M | $-49.7M | ||
| Q1 25 | $-730.0K | $32.6M | ||
| Q4 24 | $38.8M | $-32.7M | ||
| Q3 24 | $13.3M | $-40.9M | ||
| Q2 24 | $9.4M | $-46.0M | ||
| Q1 24 | $10.7M | $-56.0M |
自由现金流率ACNBRGNX
| Q4 25 | 111.4% | -174.0% | ||
| Q3 25 | 44.7% | -189.9% | ||
| Q2 25 | 35.0% | -232.8% | ||
| Q1 25 | -1.7% | 36.6% | ||
| Q4 24 | 117.0% | -154.2% | ||
| Q3 24 | 39.1% | -168.9% | ||
| Q2 24 | 28.3% | -206.2% | ||
| Q1 24 | 33.9% | -358.5% |
资本支出强度ACNBRGNX
| Q4 25 | 2.3% | 1.7% | ||
| Q3 25 | 0.8% | 1.7% | ||
| Q2 25 | 0.4% | 1.8% | ||
| Q1 25 | 1.5% | 1.2% | ||
| Q4 24 | 2.9% | 5.1% | ||
| Q3 24 | 0.7% | 1.3% | ||
| Q2 24 | 0.9% | 2.1% | ||
| Q1 24 | 0.2% | 3.6% |
现金转化率ACNBRGNX
| Q4 25 | 4.96× | — | ||
| Q3 25 | 1.56× | — | ||
| Q2 25 | 1.52× | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | 6.03× | — | ||
| Q3 24 | 1.88× | — | ||
| Q2 24 | 0.86× | — | ||
| Q1 24 | 1.60× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACNB
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
